No Association Found Between Opioid Use, Breast Cancer Recurrence
the Cancer Therapy Advisor take:
No clinical evidence was found to support a relationship between opioid prescriptions used to manage pain and risk of breast cancer recurrence, according to an article published online in the journal Cancer.
A total of 34,188 patients with incident, early stage breast cancer diagnosed between 1996 and 2008 in Denmark were identified from the Danish Breast Cancer Cooperative Group Registry. Data regarding opioid prescriptions were gathered from the Danish National Prescription Registry.
Results showed no correlation between ever-use of opioids (regardless of opioid type, strength, chronicity of use, or cumulative dose) and breast cancer recurrence (crude hazard ratio [HR], 0.98; 95% CI: 0.90, 1.1; adjusted HR, 1.0; 95% CI: 0.92, 1.1).
Furthermore, breast cancer recurrence rates were reduced among patients who used strongly (but not weakly) immunosuppressive opioids. The authors noted this could have possibly been due to channeling bias among those with a high competing risk.
The study argued the findings were important for patients with cancer given that opioids are commonly used to manage pain related to comorbid conditions.
No clinical evidence found to support a relationship between opioid prescriptions used to manage pain and risk of breast cancer recurrence.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Larotrectinib: Promising for All TRK-Positive Tumors
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy
- Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- NSCLC: Stratifying Patients With Complex EGFR Mutations